Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCVcoinfected patients on HCV antiviral therapy.
Fuster, D., Huertas, J.A., Gómez, G., Solà, R., García, J.G., Vilaró, J., Pedrol, E., Force, L., Tor, J., Sirera, G., Videla, S., Planas, R., Clotet, B. (2005). Antiviral Therapy 10, 841-847.
https://grass.upc.edu/en/publications/selection-of-publications/baseline-factors-associated-with-haematological-toxicity-that-leads-to-a-dosage-reduction-of-pegylated-interferon-alpha2a-and-ribavirin-in-hiv-and-hcvcoinfected-patients-on-hcv-antiviral-therapy
https://grass.upc.edu/++resource++plone-logo.svg
Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCVcoinfected patients on HCV antiviral therapy.
Fuster, D., Huertas, J.A., Gómez, G., Solà, R., García, J.G., Vilaró, J., Pedrol, E., Force, L., Tor, J., Sirera, G., Videla, S., Planas, R., Clotet, B. (2005). Antiviral Therapy 10, 841-847.
Share: